# Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Source: https://onco.cc/trials/nct02227251/  
OnCo record `nct02227251` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Selinexor in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.

## Summary

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT02227251 by Karyopharm Therapeutics Inc, with 244 participants planned, started 2014-11 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor, Selinexor, Selinexor. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02227251
- Phase: 2
- Setting: A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Sponsor: Karyopharm Therapeutics Inc
- Enrolled: 244

## Sources

- ClinicalTrials.gov NCT02227251: https://clinicaltrials.gov/study/NCT02227251

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Karyopharm Therapeutics](https://onco.cc/companies/karyopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct02227251.json